FDA Challenges WHOOP Over Blood Pressure Insights
In July 2025 WHOOP received an FDA warning over its Blood Pressure Insights (BPI) feature, and the dispute culminated in new FDA wellness guidance issued January 6, 2026. The article reviews the FDA's arguments—'inherent association', language and interface concerns—and WHOOP's responses, noting ambiguous wellness exemptions and implications for wearable makers seeking to report biomarker data without medical-device classification.
Key Points
- 1Documents FDA warning to WHOOP over BPI feature issued July 2025.
- 2Explains FDA's legal theories—'inherent association' and interface language—raising regulatory boundaries for wearables.
- 3Urges clearer FDA wellness guidance to enable biomarker collection without triggering medical-device pathways.
Scoring Rationale
High-impact, official FDA guidance and industry analysis elevates regulatory clarity; limited novel technical breakthroughs or AI-specific implications reduce broader ML significance.
Sources
Public references used for this report.
Practice interview problems based on real data
1,625 SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems
